Abstract
The commonest malignant condition to present to the orthopaedic surgeon is metastatic bone disease and many malignant pathological fractures are managed in orthopaedic trauma units [1]. The skeleton is both the most common site of metastasis and the site that produces the greatest morbidity for patients [2,3]. Published in 2022, the British Orthopaedic Association's Standards for Trauma (BOAST) focussing on Metastatic Bone Disease (MBD), produced in conjunction with the British Orthopaedic Oncology Society (BOOS), provides a comprehensive set of auditable recommendations for the early management of such patients [4].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
